ArticleBritish journal of clinical pharmacology2022

Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.

Helena Edlund et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.